PortfoliosLab logo
PAHC vs. BMY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PAHC and BMY is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

PAHC vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Phibro Animal Health Corporation (PAHC) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

PAHC:

0.65

BMY:

0.30

Sortino Ratio

PAHC:

1.48

BMY:

0.76

Omega Ratio

PAHC:

1.18

BMY:

1.09

Calmar Ratio

PAHC:

0.58

BMY:

0.22

Martin Ratio

PAHC:

2.86

BMY:

1.34

Ulcer Index

PAHC:

12.98%

BMY:

7.97%

Daily Std Dev

PAHC:

46.76%

BMY:

30.47%

Max Drawdown

PAHC:

-79.60%

BMY:

-70.62%

Current Drawdown

PAHC:

-50.43%

BMY:

-36.34%

Fundamentals

Market Cap

PAHC:

$910.79M

BMY:

$94.53B

EPS

PAHC:

$0.48

BMY:

$2.68

PE Ratio

PAHC:

46.81

BMY:

17.33

PEG Ratio

PAHC:

1.66

BMY:

2.26

PS Ratio

PAHC:

0.82

BMY:

1.98

PB Ratio

PAHC:

3.65

BMY:

5.57

Total Revenue (TTM)

PAHC:

$842.86M

BMY:

$47.64B

Gross Profit (TTM)

PAHC:

$272.14M

BMY:

$31.43B

EBITDA (TTM)

PAHC:

$77.58M

BMY:

$16.18B

Returns By Period

In the year-to-date period, PAHC achieves a 7.54% return, which is significantly higher than BMY's -16.07% return. Over the past 10 years, PAHC has underperformed BMY with an annualized return of -2.56%, while BMY has yielded a comparatively higher -0.51% annualized return.


PAHC

YTD

7.54%

1M

26.81%

6M

-4.83%

1Y

31.02%

5Y*

2.50%

10Y*

-2.56%

BMY

YTD

-16.07%

1M

-7.95%

6M

-12.32%

1Y

8.44%

5Y*

-2.31%

10Y*

-0.51%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PAHC vs. BMY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PAHC
The Risk-Adjusted Performance Rank of PAHC is 7676
Overall Rank
The Sharpe Ratio Rank of PAHC is 7676
Sharpe Ratio Rank
The Sortino Ratio Rank of PAHC is 7878
Sortino Ratio Rank
The Omega Ratio Rank of PAHC is 7373
Omega Ratio Rank
The Calmar Ratio Rank of PAHC is 7575
Calmar Ratio Rank
The Martin Ratio Rank of PAHC is 7979
Martin Ratio Rank

BMY
The Risk-Adjusted Performance Rank of BMY is 6262
Overall Rank
The Sharpe Ratio Rank of BMY is 6464
Sharpe Ratio Rank
The Sortino Ratio Rank of BMY is 6060
Sortino Ratio Rank
The Omega Ratio Rank of BMY is 5757
Omega Ratio Rank
The Calmar Ratio Rank of BMY is 6262
Calmar Ratio Rank
The Martin Ratio Rank of BMY is 6868
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PAHC vs. BMY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Phibro Animal Health Corporation (PAHC) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current PAHC Sharpe Ratio is 0.65, which is higher than the BMY Sharpe Ratio of 0.30. The chart below compares the historical Sharpe Ratios of PAHC and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

PAHC vs. BMY - Dividend Comparison

PAHC's dividend yield for the trailing twelve months is around 2.14%, less than BMY's 5.25% yield.


TTM20242023202220212020201920182017201620152014
PAHC
Phibro Animal Health Corporation
2.14%2.29%4.15%3.58%2.35%2.47%1.93%1.31%1.19%1.37%1.33%0.63%
BMY
Bristol-Myers Squibb Company
5.25%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%2.46%

Drawdowns

PAHC vs. BMY - Drawdown Comparison

The maximum PAHC drawdown since its inception was -79.60%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for PAHC and BMY. For additional features, visit the drawdowns tool.


Loading data...

Volatility

PAHC vs. BMY - Volatility Comparison

Phibro Animal Health Corporation (PAHC) has a higher volatility of 20.02% compared to Bristol-Myers Squibb Company (BMY) at 10.06%. This indicates that PAHC's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

PAHC vs. BMY - Financials Comparison

This section allows you to compare key financial metrics between Phibro Animal Health Corporation and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B20212022202320242025
309.26M
11.20B
(PAHC) Total Revenue
(BMY) Total Revenue
Values in USD except per share items

PAHC vs. BMY - Profitability Comparison

The chart below illustrates the profitability comparison between Phibro Animal Health Corporation and Bristol-Myers Squibb Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%40.0%50.0%60.0%70.0%80.0%20212022202320242025
32.9%
72.9%
(PAHC) Gross Margin
(BMY) Gross Margin
PAHC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Phibro Animal Health Corporation reported a gross profit of 101.87M and revenue of 309.26M. Therefore, the gross margin over that period was 32.9%.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.

PAHC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Phibro Animal Health Corporation reported an operating income of 25.53M and revenue of 309.26M, resulting in an operating margin of 8.3%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.

PAHC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Phibro Animal Health Corporation reported a net income of 3.19M and revenue of 309.26M, resulting in a net margin of 1.0%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.